Galen Clinic

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• CIDP (chronic inflammatory demyelinating polyneuropathy)3 trials
• Myasthenia gravis3 trials
• Multiple sclerosis2 trials

Phase

• Phase 35 trials
• Phase 23 trials

Status

• Completed3 trials
• Recruiting3 trials
• Active, not recruiting2 trials

Lead sponsor

• argenx2 trials
• Novartis Pharmaceuticals2 trials
• Eli Lilly and Company1 trial
• Hoffmann-La Roche1 trial
• Immunovant Sciences GmbH1 trial
• and 1 more

Running trials

• Recruiting

  A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

  NCT07091630· Phase 3· argenx· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  NCT06920004· Phase 3· argenx· Source

• Active, not recruiting

  A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

  NCT06517758· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

  NCT06414954· Phase 2· NMD Pharma A/S· Source

  Contact: Urszula Chyrchel-Paszkiewicz

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

  NCT04035005· Phase 3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Myasthenia gravis1 recruiting

Closed trials

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

  NCT06220669· Phase 2· Eli Lilly and Company· Source

• Completed

  Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP.

  2024-512646-42-00· Phase 2· Immunovant Sciences GmbH· Source